Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02903472 · ClinicalTrials.gov registry record
Gastrointestinal and Urinary Tract Microbiome After SCI
A clinical trial, sponsored by University of British Columbia.
- Completed
- Registry status
- 43
- Enrollment target
NCT02903472: Completed study, sponsored by University of British Columbia.
NCT02903472 is a clinical trial that has completed, run by University of British Columbia. The registered enrollment target is 43 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02903472 has completed, sponsored by University of British Columbia.
- COMPLETED
- Registry status
- 43 participants
- Enrollment target
Study Summary
Changes in the GI microbiota and/or metabolomics have been linked to evolving transformations in immune system function and infection rates in experimental SCI in animal models. A recent study involving chronic survivors of SCI show distinct GI microbiome changes in comparison to healthy controls. GI microbial metabolism of dietary components has been causally linked to various health conditions, such as cardiovascular disease, infections, which is an ongoing concern for chronic SCI survivors. It is probable that alterations of GI microbiota are established acutely after SCI and could subsequently alter medical care and impact health outcomes for people living with SCI. This project is a pilot study to describe any changes in the GI and urinary tract microbiota as they appear over the first year after SCI. When available, data on factors, other than SCI, that may impact change in the gut microbiome after SCI will also be noted, including: * the level and severity of SCI, * the time since SCI, * the person's immune profile, * the antibiotic regimen of the individual and time since antibiotic administration, * the incidence and type of infections after SCI and * the person's diet or activities after SCI
Primary Outcome
Establishing the correlations between changes in neurological and functional capabilities in individuals with SCI and difference in the gut intestinal (GI) microbiota or metabolome and determining how such changes contribute to increased rates of infections
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2017-09-01 |
| Est. Completion | 2020-12-31 |
What the finished NCT02903472 record still lists
NCT02903472 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 43 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02903472 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02903472 about?
NCT02903472 is a clinical study titled "Gastrointestinal and Urinary Tract Microbiome After SCI". Changes in the GI microbiota and/or metabolomics have been linked to evolving transformations in immune system function and infection rates in experimental SCI in animal models. A recent study involving chronic survivors of SCI show distinct GI microbiome changes in comparison to healthy controls. G...
What is the current status of trial NCT02903472?
This trial is currently completed. The enrollment target is 43 participants. The study started on 2017-09-01. Estimated completion is 2020-12-31.
Who is sponsoring clinical trial NCT02903472?
This trial is sponsored by University of British Columbia, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI